Alzheimer and Lithium

Lithium, a well-established therapeutic option for the management of bipolar disorder and major depression, has also been regarded as a neuroprotective agent and a candidate drug for disease-modification in certain neurodegenerative disorders like e.g. Alzheimer's disease. Lithium inhibits the phosphorylation of glycogen-synthase-kinase 3-alpha and -beta (GSK3A and GSK3B), which are related to amyloid precursor protein processing and tau hyperphosphorylation in pathological conditions, respectively. Microdose lithium treatment stabilizes the cognitive impairment in AD patients.


Interactions15Proteins/Genes6Chemical compounds/drugs1
Biological Process(GO)0Phenotype2

Biological Process(GO)

Chemical compounds/drugs